These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11924889)

  • 1. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids.
    Vaddadi KS; Soosai E; Chiu E; Dingjan P
    Neuroreport; 2002 Jan; 13(1):29-33. PubMed ID: 11924889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
    Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
    Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
    van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine for Huntington's disease: an open label study.
    Bonelli RM; Mahnert FA; Niederwieser G
    Clin Neuropharmacol; 2002; 25(5):263-5. PubMed ID: 12410058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial.
    Verbessem P; Lemiere J; Eijnde BO; Swinnen S; Vanhees L; Van Leemputte M; Hespel P; Dom R
    Neurology; 2003 Oct; 61(7):925-30. PubMed ID: 14557561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
    Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
    Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.
    Gelderblom H; Wüstenberg T; McLean T; Mütze L; Fischer W; Saft C; Hoffmann R; Süssmuth S; Schlattmann P; van Duijn E; Landwehrmeyer B; Priller J
    PLoS One; 2017; 12(3):e0173872. PubMed ID: 28323838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease.
    Winder JY; Achterberg WP; Gardiner SL; Roos RAC
    Eur J Neurol; 2019 May; 26(5):780-785. PubMed ID: 30576046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, placebo-controlled trial of latrepirdine in Huntington disease.
    Kieburtz K; McDermott MP; Voss TS; Corey-Bloom J; Deuel LM; Dorsey ER; Factor S; Geschwind MD; Hodgeman K; Kayson E; Noonberg S; Pourfar M; Rabinowitz K; Ravina B; Sanchez-Ramos J; Seely L; Walker F; Feigin A;
    Arch Neurol; 2010 Feb; 67(2):154-60. PubMed ID: 20142523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
    Ferreira JJ; Rosser A; Craufurd D; Squitieri F; Mallard N; Landwehrmeyer B
    Mov Disord; 2015 Sep; 30(10):1426-9. PubMed ID: 26175332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study.
    Huntington Study Group TREND-HD Investigators
    Arch Neurol; 2008 Dec; 65(12):1582-9. PubMed ID: 19064745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
    McGarry A; Kieburtz K; Abler V; Grachev ID; Gandhi S; Auinger P; Papapetropoulos S; Hayden M
    J Huntingtons Dis; 2017; 6(3):189-199. PubMed ID: 28826192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
    López-Sendón Moreno JL; García Caldentey J; Trigo Cubillo P; Ruiz Romero C; García Ribas G; Alonso Arias MA; García de Yébenes MJ; Tolón RM; Galve-Roperh I; Sagredo O; Valdeolivas S; Resel E; Ortega-Gutierrez S; García-Bermejo ML; Fernández Ruiz J; Guzmán M; García de Yébenes Prous J
    J Neurol; 2016 Jul; 263(7):1390-400. PubMed ID: 27159993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study.
    Youssov K; Dolbeau G; Maison P; Boissé MF; Cleret de Langavant L; Roos RA; Bachoud-Lévi AC
    Mov Disord; 2013 Dec; 28(14):1995-2001. PubMed ID: 24123464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
    Puri BK; Leavitt BR; Hayden MR; Ross CA; Rosenblatt A; Greenamyre JT; Hersch S; Vaddadi KS; Sword A; Horrobin DF; Manku M; Murck H
    Neurology; 2005 Jul; 65(2):286-92. PubMed ID: 16043801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
    Curtis A; Mitchell I; Patel S; Ives N; Rickards H
    Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.